The cannabinoid CB1 receptor antagonist, rimonabant, as a promising pharmacotherapy for alcohol dependence:: Preclinical evidence

被引：43
|
作者：
Colombo, Giancarlo
Orru, Alessandro
Lai, Paola
Cabras, Claudia
Maccioni, Paola
Rubio, Marina
Gessa, Gian Luigi
Carai, Mauro A. M.
机构：
[1] CNR, Inst Neurosci, I-00185 Rome, Italy
[2] Univ Cagliari, Dept Neurosci, Cagliari, Italy
[3] Univ Complutense, Dept Biochem & Mol Biol, E-28040 Madrid, Spain
来源：
MOLECULAR NEUROBIOLOGY | 2007年 / 36卷 / 01期
关键词：
cannabinoid CB1 receptor antagonist; rimonabant; alcohol; alcohol dependence (alcoholism); alcohol drinking and seeking behavior; animal models of alcoholism;
D O I：
10.1007/s12035-007-0017-y
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Several lines of preclinical evidence indicate the ability of the prototypic cannabinoid CB1 receptor antagonist, rimonabant, to suppress various alcohol-related behaviors, including alcohol drinking and seeking behavior and alcohol self-administration in rats and mice. Together, these data-synthetically reviewed in the present paper-suggest (a) the involvement of the cannabinoid CB1 receptor in the neural substrate controlling alcohol intake, alcohol reinforcement, and the motivational properties of alcohol and (b) that rimonabant may constitute a new and potentially effective medication for the treatment of alcohol dependence.
引用
收藏
页码：102 / 112
页数：11
相关论文
共 50 条
  • [1] The Cannabinoid CB1 Receptor Antagonist, Rimonabant, as a Promising Pharmacotherapy for Alcohol Dependence: Preclinical Evidence
    Giancarlo Colombo
    Alessandro Orrù
    Paola Lai
    Claudia Cabras
    Paola Maccioni
    Marina Rubio
    Gian Luigi Gessa
    Mauro A. M. Carai
    Molecular Neurobiology, 2007, 36 : 102 - 112
  • [2] Blockade of the Cannabinoid CB1 Receptor and Alcohol Dependence: Preclinical Evidence and Preliminary Clinical Data
    Maccioni, Paola
    Colombo, Giancarlo
    Carai, Mauro A. M.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2010, 9 (01) : 55 - 59
  • [3] Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?
    Doggrell, SA
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (12) : 2141 - 2144
  • [4] Update on rimonabant - A selective cannabinoid CB1 antagonist
    Boyd, ST
    Fremming, BA
    ANNALS OF PHARMACOTHERAPY, 2006, 40 (05) : 994 - 994
  • [5] The CB1 cannabinoid receptor antagonist rimonabant chronically prevents the nicotine-induced relapse to alcohol
    Lopez-Moreno, Jose Antonio
    Gonzalez-Cuevas, Gustavo
    Navarro, Miguel
    NEUROBIOLOGY OF DISEASE, 2007, 25 (02) : 274 - 283
  • [6] Discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats
    Jarbe, Torbjoern U. C.
    Li, Chen
    Vadivel, Subramanian K.
    Makriyannis, Alexandros
    PSYCHOPHARMACOLOGY, 2008, 198 (04) : 467 - 478
  • [7] Discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats
    Torbjörn U. C. Järbe
    Chen Li
    Subramanian K. Vadivel
    Alexandros Makriyannis
    Psychopharmacology, 2008, 198 : 467 - 478
  • [8] The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction
    Lim, Shiang Y.
    Davidson, Sean M.
    Yellon, Derek M.
    Smith, Christopher C. T.
    BASIC RESEARCH IN CARDIOLOGY, 2009, 104 (06) : 781 - 792
  • [9] Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents
    Griebel, G
    Stemmelin, J
    Scatton, B
    BIOLOGICAL PSYCHIATRY, 2005, 57 (03) : 261 - 267
  • [10] The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction
    Shiang Y. Lim
    Sean M. Davidson
    Derek M. Yellon
    Christopher C. T. Smith
    Basic Research in Cardiology, 2009, 104 : 781 - 792
12345